Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,512.32
    -1,064.05 (-2.06%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

UK cost agency says "no" to Bayer prostate cancer drug Xofigo

Reuters - UK Focus

LONDON, March 24 (Reuters) - Britain's healthcare cost agency has recommended against using Bayer (Milan: BAY.MI - news) 's new prostate cancer drug Xofigo on the state health service because the German firm did not provide evidence on how well it worked compared to other therapies.

The draft guidance from the National Institute for Health and Care Excellence (NICE (Milan: NICE.MI - news) ), issued on Monday, is now subject to consultation.

"We are disappointed not to able to recommend this drug, but we have to be confident that its benefits justify its considerable cost," said NICE Chief Executive Andrew Dillon.

Xofigo - priced at an average 24,240 pounds ($40,000) for a course of treatment but also eligible for an undisclosed discount - is a radioactive agent that migrates to parts of the body with abnormal bone growth.

Bayer clinched a $2.9 billion deal last month to acquire Norway's Algeta (Other OTC: ALGZF - news) in order to gain full control of the treatment, which the two companies developed jointly. ($1 = 0.6057 British Pounds) (Reporting by Ben Hirschler; Editing by Elaine Hardcastle)